There are so many ways you can help make a difference in the lives of patients and families today.
Thanks to the generous funding provided by the Brain Tumour Foundation of Canada and DUNN with Cancer, we are now poised to advance our research and delve deeper into elucidating key epigenetic factors that drive the progression of GBM and its resistance to therapies.
We are so grateful to the BTFC and DUNN with Cancer for the many levels of support they provide to the brain cancer research community. BTFC supports new ideas, innovation and transformative thinking about incredibly challenging problems like how to develop new treatments for a highly treatment-resistant brain tumour such as GBM.
This funding has enabled us to continue the promising research on targeting pannexin channels to stop communication between cells and reduce the growth and spread of glioblastoma tumours. Thanks to this funding we can support the technicians, graduate students, and expensive supplies we need to use in the lab to carry out this research.
On behalf of my collaborating investigators and myself, I would like to express immense gratitude to all of you for supporting our research that we know will have profound impact on the practice and delivery of care for pediatric brain tumour patients across Canada.
Cancer treatment has undergone many advancements in the past decade to improve patient quality of life and to provide new and improved treatment strategies. However, there is still a lot of work to be done, with current treatment strategies succumbing to resistance, and other more rare cancers remaining undruggable.
Glioblastoma (a fast-growing brain cancer) is the most common malignant brain tumor in adults. As a devastating diagnosis with a high mortality rate and rapid loss of function and independence, it is imperative to consider factors such as symptom management, maintaining independence and preserving or improving quality of life for the duration of the patients’ life.